0001606498falseOctober 20, 202000016064982020-10-202020-10-2000016064982020-08-312020-08-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: October 20, 2020
(Date of earliest event reported)
Commission file number 001-36440
AVNS-20201020_G1.JPG
AVANOS MEDICAL, INC.
(Exact name of registrant as specified in its charter)

Delaware 46-4987888
(State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.)
5405 Windward Parkway
Suite 100 South
Alpharetta, Georgia 30004
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code: (844) 428-2667
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol Name of exchange on which registered
Common Stock - $0.01 Par Value AVNS New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On October 20, 2020, John W. Wesley, the Company’s Senior Vice President and General Counsel, notified the Company that he is retiring from the Company, effective as of December 1, 2020. Prior to that date, Mr. Wesley will continue to serve as a Senior Vice President at the Company and assist with an orderly transition of his responsibilities to S. Ross Mansbach, who has been appointed as Senior Vice President and Interim General Counsel, effective October 22, 2020, in addition to his responsibilities as the Company’s Corporate Secretary.

Item 9.01    Financial Statements and Exhibits
(d)Exhibits.
    The following exhibits are filed with this Current Report on Form 8-K:
Exhibit No. Description
101.SCH XBRL Taxonomy Extension Schema Document
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF XBRL Taxonomy Extension Definition Linkbase Document
101.LAB XBRL Taxonomy Extension Label Linkbase Document
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document




SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    
AVANOS MEDICAL, INC.
Date: October 26, 2020 By: /s/ S. Ross Mansbach
S. Ross Mansbach
Senior Vice President, Interim General Counsel and Corporate Secretary


Avanos Medical (NYSE:AVNS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Avanos Medical Charts.
Avanos Medical (NYSE:AVNS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Avanos Medical Charts.